---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-005224"
form_type: "8-K"
ticker: null
cik: "0001532346"
company_name: "Atreca, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:22:43.559098+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Atreca suspends lead candidate ATRC-101, cuts 40% of staff; Q2 net loss $19.2M

## Summary
- Suspension of ATRC-101 development and ~40% workforce reduction; estimated restructuring costs of $1.6M in Q3 2023.
- Q2 2023 net loss of $19.2M ($0.49 per share); cash and investments totaled $38.5M as of June 30, 2023.
- R&D expenses $12.9M and G&A expenses $6.8M for Q2 2023, including stock-based compensation.
- Focus shifts to preclinical ADC APN-497444; expects to nominate clinical candidate in 2023 and IND in late 2024/early 2025.
- Cash runway expected to fund operations through early 2024; company evaluating additional cost-saving initiatives.

## SEC filing metadata
- accession: 0001171843-23-005224
- form_type: 8-K
- cik: 0001532346
- company_name: Atreca, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1532346/000117184323005224/0001171843-23-005224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1532346/000117184323005224/f8k_081023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-005224
- JSON: https://secwatch.observer/filing/0001171843-23-005224.json
- Plain text: https://secwatch.observer/filing/0001171843-23-005224.txt

## Key facts
- Restructurings & Charges
  Atreca, Inc. announced a restructuring with charges of approximately $1.6 million affecting operations (approximately 40% of its current employees).
  - Type: restructuring
  - Charge: approximately $1.6 million
  - Affected area: operations
  - Headcount: approximately 40% of its current employees
  source text: On August 10, 2023, the Company implemented and announced a corporate reorganization of its operations. As part of the reorganization, the Company is undertaking cost-saving initiatives, including a workforce reduction of approximately 40% of its current employees and the suspension of the development of ATRC-101, its former lead product candidate. The total cost related to the workforce reduction is estimated to be approximately $1.6 million, all of which is cash-based expenditures related primarily to severance payments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1532346/000117184323005224/0001171843-23-005224-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.